Login to Your Account

Pharma: Clinic Roundup

Wednesday, August 1, 2012
• Pfizer Inc., of New York, reported top-line results from the Phase III ORAL Start study of JAK inhibitor tofacitinib in moderate to severe active rheumatoid arthritis (RA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription